Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes
Lymphoproliferative Disorders
Baylor College of MedicineCell therapyPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
19 Active assets in the Lymphoproliferative Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 2 | BB |
Tabelecleucel Pierre Fabre Medicament | Phase 3 | BB |
Ibrutinib Oncternal Therapeutics, Inc | Phase 3 | B |
Zilovertamab Oncternal Therapeutics, Inc | Phase 3 | B |
ALECTINIB Cancer Research UK | Phase 2/3 | B |
View all 34 →
Same molecule, other indications
Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →